Stockscreener 앱 받기
1.24
2.48%
0.03
시간 외 거래:
1.79
0.55
+44.35%
전일 마감가:
$1.21
열려 있는:
$1.2
하루 거래량:
10.60M
Relative Volume:
8.98
시가총액:
$21.15M
수익:
-
순이익/손실:
$-11.24M
주가수익비율:
-1.6284
EPS:
-0.7615
순현금흐름:
$-4.79M
1주 성능:
-0.80%
1개월 성능:
-10.79%
6개월 성능:
+7.83%
1년 성능:
+105.74%
1일 변동 폭
$1.20
$1.25
1주일 범위
$1.18
$1.28
52주 변동 폭
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
명칭
Mira Pharmaceuticals Inc
전화
813-369-5150
주소
1200 BRICKELL AVENUE, MIAMI
MIRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.24 | 21.15M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
779.28 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.56 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.82 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
190.75 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
123.81 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology - Knoxville News Sentinel
MIRA Pharmaceuticals’ ketamine analog accepted for publication By Investing.com - Investing.com Nigeria
Breakthrough Ketamine Alternative Passes Key Scientific Review: Phase 2 Trial Coming - Stock Titan
EON Resources Inc. Announcement - The Oklahoman
MIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology Journal - TipRanks
Two Sigma Investments LP Buys Shares of 24,317 MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
Citadel Advisors LLC Makes New $112,000 Investment in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - USA Today
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Shares Acquired by Northern Trust Corp - Defense World
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times
MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | - GuruFocus
MIRA Pharmaceuticals (MIRA) Sets Sights on Major Advancements | MIRA Stock News - GuruFocus
MIRA Pharmaceuticals Joins BIO Convention for Strategic Opportunities - TipRanks
MIRA's Novel Pain Drug Shows Promise: Phase 1 Success Leads to Phase 2 Plans as Acquisition Nears - Stock Titan
MIRA Pharmaceuticals announces clinical progress and acquisition update - Investing.com
MIRA Pharmaceuticals announces clinical progress and acquisition update By Investing.com - Investing.com Nigeria
MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN
MIRA Pharmaceuticals appoints new CFO - Investing.com Australia
MIRA Pharmaceuticals Appoints New Chief Financial Officer - TipRanks
MIRA Pharmaceuticals appoints new CFO By Investing.com - Investing.com UK
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals (MIRA) Projected to Post Earnings on Monday - Defense World
Why Mira Pharmaceuticals Inc (NASDAQ: MIRA) Is A Great Stock Pick For Momentum Investors - Stocksregister
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong By Stocktwits - Investing.com India
MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60M - TipRanks
MIRA Pharmaceuticals to acquire SKNY in strategic move - Investing.com
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review - Corsicana Daily Sun
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Benzinga
Renaissance Technologies LLC Takes Position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity - The Joplin Globe
MIRA Achieves Positive Safety Results in Neurotoxicity Study | M - GuruFocus
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study - AOL.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 - Investing.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 By Investing.com - Investing.com UK
MIRA Pharmaceuticals Completes Key Neurotoxicity Study for Ketamir-2 - TipRanks
Breakthrough: New Drug Outperforms Ketamine in FDA Brain Safety StudyZero Toxicity Detected - Stock Titan
Pharmaceutical Stock Jumps After Key Trial Findings - MSN
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April - Defense World
Mira Pharmaceuticals Inc [MIRA] moved up 7.08: Why It’s Important - dbtnews.com
Financial Metrics Unveiled: Mira Pharmaceuticals Inc (MIRA)’s Key Ratios in the Spotlight - DWinneX
MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN
Mira Pharmaceuticals announces key drug development milestone By Investing.com - Investing.com Canada
Mira Pharmaceuticals announces key drug development milestone - Investing.com Australia
MIRA Pharmaceuticals (MIRA) Advances Ketamir-2 Formulations in P - GuruFocus
Mira Pharmaceuticals Inc (MIRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mira Pharmaceuticals Inc 주식 (MIRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Aminov Erez | Chief Executive Officer |
Nov 20 '24 |
Sale |
1.27 |
44,590 |
56,629 |
1,061,200 |
0.53%
0.20%
자본화:
|
볼륨(24시간):